Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 17,226

Document Document Title
WO/2019/216651A1
A peptide of the present invention, which is composed of a relatively short amino acid sequence, is easily absorbed in the body and excellent in anti-wrinkle efficacy, can promote collagen production, and inhibit aging genes. Therefore, ...  
WO/2019/216466A1
The present invention provides novel cyclic dipeptidase. The cyclic dipeptidase according to present invention could be used to produce antibacterial cyclic dipeptide. By using this cyclic dipeptidase it is possible to make a new microor...  
WO/2019/211829A1
Compositions and methods for treating malignant gliomas such as glioblastoma are provided, comprising a combination of a peptide conjugate comprising an amino acid sequence derived from the N-terminus of the receptor PAR-1, and the chemo...  
WO/2019/211434A1
The present invention relates to dipeptidyl ketoamide m-methoxyphenyl derivatives and their use in the treatment of diseases and conditions associated with elevated calpain activity, such as heart injury caused by infarction, ischemia wi...  
WO/2019/213386A1
The disclosure provides proteasome inhibitors that can be used to halt cell division of rapidly dividing cells by preventing the degradation of cell cycle-regulating proteins, such as cyclins, cyclin-dependent kinase inhibitors, and p53....  
WO/2019/208700A1
Provided is a novel ingredient having fatigue prevention and recovery effects. This dipeptide is selected from among: (D)Ile-(D)Pro, (D)Leu-(D)Pro, (D)Pro-(D)Ile, D)Pro-(D)Leu, (D)Val-(D)Pro, (D)Pro-(D)Val, (D)Leu-(D)Hyp, (D)Ile-(D)Hyp, ...  
WO/2019/208701A1
Provided is a novel anti-inflammatory agent. This anti-inflammatory agent has as an active ingredient a dipeptide selected from among: (D)Ile-(D)Pro, (D)Leu-(D)Pro, (D)Pro-(D)Ile, D)Pro-(D)Leu, (D)Val-(D)Pro, (D)Pro-(D)Val, (D)Leu-(D)Hyp...  
WO/2019/206853A1
The present invention provides compounds of formula (I) wherein X1, X2, R1 to R6 and A are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the ...  
WO/2019/210054A1
Provided are novel dipeptide repeat (DPR) specific antibodies (e.g., human-derived antibodies) as well as synthetic variants and biotechnological derivatives thereof, capable of binding C9orf72 poly-glycine-alanine DPRs, as well as metho...  
WO/2019/168149A9
The present invention addresses the problem of providing: a peptide having an excellent effect to prevent the deterioration in a cognitive function and to improve a cognitive function; and a use of the peptide. In the present invention, ...  
WO/2019/198813A1
The present invention addresses the problem of providing a photosensitive cytotoxic agent which can be used for treatments against a wide variety of types of cancer cells, has more superior versatility, and can be used as a therapeutic a...  
WO/2019/197602A1
A compound with the formula I: (I) and salts and solvates thereof, wherein: R" is a group of formula II: (II) where each of n and m are independently selected from 1, 2 and 3.  
WO/2019/136310A3
Disclosed herein are compounds for the treatment of neurodegenerative diseases and compositions comprising the same.  
WO/2019/195080A1
Disclosed are crystalline forms of L-Lys(Boc)-Phe-NH2 and Boc-D-Arg-DMT.  
WO/2019/186497A1
The disclosure relates to pharmaceutical compositions, to methods of preparing such compositions, and to methods for using such compositions for treating or preventing a disease or condition associated with arginase activity.  
WO/2019/187534A1
The purpose of the present invention is to provide an industrially practicable method for producing reduced glutathione by reducing oxidized glutathione. The method for producing reduced glutathione according to the present invention is ...  
WO/2019/189853A1
Provided is a biologically relevant substance to which is bonded a high-molecular-weight polyethylene glycol derivative that does not cause vacuolation in cells. A biologically relevant substance to which is bonded a degradable polyethyl...  
WO/2019/185572A1
The present invention provides compounds of formula (I) wherein X, L1 and R1 to R10 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the com...  
WO/2019/189733A1
The present invention provides an oxidized-glutathione-containing solid composition that can be produced by a simple method, has low deliquescence, and is easy to handle. The present invention pertains to a solid composition containing a...  
WO/2019/186561A1
Pharmaceutical compositions comprising specific tetrapeptides, for use in reducing the release or inhibiting the activity of inflammatory cytokines and mediator and treatment of diseases and disorders associated with these cytokines and ...  
WO/2019/181901A1
The purpose of the present invention is to provide a compound that acts to inhibit anoikis in cells and enhance cell survival rates, and a compound that induces cell infiltration and enhances cell engraftment. The present invention provi...  
WO/2019/183556A1
The present technology provides compounds of Formula I (or pharmaceutically acceptable salts and/or solvates thereof) that are useful in treating a CNS-related disorder such as schizophrenia, schizoaffective disorder, migraine, depressio...  
WO/2019/183265A1
The presently disclosed subject matter relates to peptides and flavor compositions that include at least one, two, three, four, five or more peptide compounds, and screening methods for identifying the same. The flavor compositions can b...  
WO/2019/182483A1
The invention relates to the field of bioorganic chemistry and concerns novel substrates for determining the enzymatic activity of peptidases. A compound of general formula (1) A-Xaa-Gln-B is proposed as a highly specific and selective s...  
WO/2019/173911A1
Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-e...  
WO/2019/172210A1
[Problem] To provide a novel compound having great potential as a prodrug-type anticancer agent. [Solution] A compound represented by general formula (I) or a salt thereof  
WO/2019/172834A1
The present invention relates to a process for the preparation of certain 1,5-benzothiazepine compounds, and in particular toa process for the preparation of elobixibat. The process can be carried out under mild and safe conditions and m...  
WO/2019/166347A1
The present invention relates to a family of peptides which are able to interfere in the formation of complex Munc18-Syntaxin-1 and, hence, are useful in the prevention and/or treatment of neuronal exocytosis and/or muscle contractility ...  
WO/2018/094023A3
A pharmaceutical composition comprising a cyclo-dipeptide and use thereof for treatment of a wound. The cyclo-dipeptide can be Cyclo-His-Pro and the pharmaceutical composition can suitable for topical application to a wound. The composit...  
WO/2019/167034A1
Non-antimicrobial compounds, methods and compositions comprising the same for treating medical conditions associated with pathogenic microorganism in a subject, as well as drug-resistant strains thereof, which are effective in immunopote...  
WO/2019/168149A1
The present invention addresses the problem of providing: a peptide having an excellent effect to prevent the deterioration in a cognitive function and to improve a cognitive function; and a use of the peptide. In the present invention, ...  
WO/2019/164987A1
Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities t...  
WO/2019/161487A1
Beef protein was hydrolyzed with each of six commercial enzymes (alcalase, chymotrypsin, trypsin, pepsin, flavourzyme, and thermoase). Electronic tongue measurements showed that the hydrolysates had significantly (p < 0.05) lower bitter ...  
WO/2019/160024A1
Provided is a composition for reducing blood pressure and/or reducing neutral fats that has few side effects and is very safe. The composition for reducing blood pressure and/or for reducing neutral fats comprises a casein hydrolysate an...  
WO/2019/160037A1
The purpose of the present invention is to provide methods for producing a carboxamide compound, a sulfonamide compound, and an ester compound using an acid halide. The methods for producing a carboxamide compound, a sulfonamide compound...  
WO/2019/160916A1
Provided herein are heterocyclic compounds useful for imaging Granzyme B. Methods of imaging Granzyme B, combination therapies, and kits comprising the Granzyme B imaging agents are also provided.  
WO/2019/154053A1
Disclosed are a new compound that inhibits IAP and the use thereof. In particular, the present invention relates to a compound which is an IAP inhibitor, or a stereoisomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmace...  
WO/2019/104851A4
Beta-hydroxybutyryl-amino acid compounds represented by formulas I, II, III, IV, V, VI, VII, VIII, IX and X, a preparation method therefor and use thereof. The compounds have antitumor activity and can be used for weight loss, anti-aging...  
WO/2019/156630A1
Disclosed herein is a membrane having less than 15% water content, comprising a modified agarose that is covalently linked to a cell attachment signal such as an amino acid, a peptide and a chemical moiety that cells recognize and intera...  
WO/2019/155464A1
The invention disclosed herein concerns a novel class of compounds suitable for the treatment of neurodegenerative diseases, such as Parkinson's Disease.  
WO/2019/157014A1
A series of subunit selective allosteric modulators of NMDA receptor function according to Formula (I) is provided herein. Also provided is a method of treating neurological disorders such as Alzheimer's disease Parkinson's disease, schi...  
WO/2019/154151A1
The present invention relates to an intermediate compound of formula II-1 or formula II-2 or a salt thereof, and a preparation method therefor. The present invention further relates to a process for synthesizing a compound of formula I b...  
WO/2019/151384A1
One embodiment of the present invention relates to novel substances, etc., which are: [1] a compound, etc., represented by formula (A1) or formula (B1); [2] a compound, etc., represented by formula (A2) or formula (B2); [3] a compound, e...  
WO/2019/151320A1
The problem addressed by the present invention is to provide a technique for improving the anticancer effect of ubenimex, especially the anticancer effect on solid cancers. The problem is solved by a compound containing a chain-form stru...  
WO/2019/151137A1
The purpose of this invention is to provide a substance which, by being added to food, promotes intracerebral discharge of both noradrenaline and serotonin, thereby preventing cranial brain disease and improving brain function. A specifi...  
WO/2017/021004A8
The present invention relates to chromogenic and fluorogenic substrates that can be used for the highly sensitive and selective detection of the activity of serine proteases. The present invention further relates to methods for the detec...  
WO/2019/100004A3
The subject invention provides compositions and methods for alleviating pain. Specifically, the subject invention provides pharmaceutical formulations of polymers, and/or their salts, having advantageous μ-opioid receptor binding activity.  
WO/2019/147182A1
The present invention relates to novel antiatherosclerotic compounds of formula (I), their pharmaceutically acceptable salts, their isomers, and processes for preparing them. The present invention further provides pharmaceutical composit...  
WO/2019/137247A1
The present invention relates to the field of virology, and specifically discloses a short peptide having a dengue virus replication inhibition function and an application thereof. The amino acid sequence of the short peptide provided in...  
WO/2019/104851A3
Beta-hydroxybutyryl-amino acid compounds represented by formulas I, II, III, IV, V, VI, VII, VIII, IX and X, a preparation method therefor and use thereof. The compounds have antitumor activity and can be used for weight loss, anti-aging...  

Matches 1 - 50 out of 17,226